Literature DB >> 10066098

Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma.

M F Roesdi1, T J Postma, O S Hoekstra, C J van Groeningen, J G Wolbers, J J Heimans.   

Abstract

Combination chemotherapy with procarbazine, CCNU and vincristine (PCV) may be effective in patients with recurrent glioma. Response monitoring is mandatory, but radiological response evaluation is often difficult. We evaluated Thallium-201 (201Tl) SPECT as a response parameter in ten patients treated with intensive PCV chemotherapy for recurrent glioma. 201Tl-SPECT studies showed early changes (decreasing volume and intensity) in nine patients and these changes were more pronounced than radiological findings. 201Tl-SPECT results after completion of chemotherapy seemed to correlate with clininal findings during follow up. We conclude that 201Tl-SPECT may contribute to the assessment of response in patients treated with PCV chemotherapy for recurrent glioma.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 10066098     DOI： 10.1023/a:1006090807678

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  14 in total

1.  Chemotherapy of high-grade gliomas: beginning of a new era or the end of the old?

Authors:  M Brada; G Sharpe
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

2.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

3.  Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.

Authors:  V A Levin; P Silver; J Hannigan; W M Wara; P H Gutin; R L Davis; C B Wilson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-02       Impact factor: 7.038

4.  Reassessment of quantitative thallium-201 brain SPECT for miscellaneous brain tumors.

Authors:  S Kosuda; H Fujii; S Aoki; K Suzuki; Y Tanaka; O Nakamura; N Shidara
Journal:  Ann Nucl Med       Date:  1993-11       Impact factor: 2.668

5.  Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors.

Authors:  V A Levin; M S Edwards; D C Wright; M L Seager; T P Schimberg; J J Townsend; C B Wilson
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar

6.  Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

Authors:  H A Fine; K B Dear; J S Loeffler; P M Black; G P Canellos
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

7.  Brain radiation lesions: MR imaging.

Authors:  G C Dooms; S Hecht; M Brant-Zawadzki; Y Berthiaume; D Norman; T H Newton
Journal:  Radiology       Date:  1986-01       Impact factor: 11.105

8.  Thallium-201 brain tumor imaging: a comparative study with pathologic correlation.

Authors:  W D Kaplan; T Takvorian; J H Morris; C L Rumbaugh; B T Connolly; H L Atkins
Journal:  J Nucl Med       Date:  1987-01       Impact factor: 10.057

9.  Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology.

Authors:  W J Slizofski; L Krishna; C D Katsetos; P Black; C Miyamoto; S J Brown; J Vender; A Chevres; A S Khan; J McEwan
Journal:  Cancer       Date:  1994-12-15       Impact factor: 6.860

10.  Successful chemotherapy for recurrent malignant oligodendroglioma.

Authors:  J G Cairncross; D R Macdonald
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422
View more
  5 in total

1.  MRI and thallium-201 SPECT in the prediction of survival in glioma.

Authors:  Maaike J Vos; Johannes Berkhof; Otto S Hoekstra; Ingeborg Bosma; Eefje M Sizoo; Jan J Heimans; Jaap C Reijneveld; Esther Sanchez; Frank J Lagerwaard; Jan Buter; David P Noske; Tjeerd J Postma
Journal:  Neuroradiology       Date:  2011-07-14       Impact factor: 2.804

2.  Thallium-201 SPECT: the optimal prediction of response in glioma therapy.

Authors:  Maaike J Vos; Johannes Berkhof; Tjeerd J Postma; Otto S Hoekstra; Frederik Barkhof; Jan J Heimans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-29       Impact factor: 9.236

3.  Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.

Authors:  Bich-Ngoc-Thanh Tang; Niloufar Sadeghi; Fabrice Branle; Olivier De Witte; David Wikler; Serge Goldman
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

4.  Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas.

Authors:  V Vallejos; C Balaña; M Fraile; Y Roussos; J Capellades; P Cuadras; R Ballester; A Ley; A Arellano; R Rosell
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

5.  Technetium-99m sestamibi brain SPECT in the follow-up of glioma for evaluation of response to chemotherapy: first results.

Authors:  Florence Prigent-Le Jeune; François Dubois; Sarah Perez; Serge Blond; Marc Steinling
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-19       Impact factor: 9.236
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.